Rep. Carolyn Maloney (D-N.Y) on Tuesday asked the FTC to investigate whether AbbVie's pricing and business practices broke the law.

AbbVie Abused Humira’s Orphan Drug Designation, House Panel Says

A U.S. House committee alleged Tuesday that AbbVie gamed the federal orphan drug program to boost profits for its anti-inflammatory drug Humira—by far, the top-selling medicine in the United States.

Four types of hospitals that participate in the 340B program are unable to purchase Humira and other drugs with orphan disease designations at reduced 340B prices. Legislation has been re-introduced to partially lift the ban.

A U.S. House committee alleged Tuesday that AbbVie gamed the federal orphan drug program to boost profits for its anti-inflammatory drug Humira—by far, the top-selling medicine in the United States.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report